Hospital del Mar
Hospital del Mar
Barcelona, Barcelona, Spain17 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 2 | 2026-10-05 | NCT06582628 | |
| A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis | Non-cystic Fibrosis Bronchiectasis | Recruiting | Phase 2 | 2026-08-06 | NCT06559150 | |
| Immersive VR to Reduce Stress, Anxiety, and Pain During PICC/Midline Placement | Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, anxiety, anxiety disorder, psychiatric disorder | Not yet recruiting | Not applicable | 2026-07-10 | NCT07696156 | |
| Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis | cardiovascular disorder, endocarditis, heart disorder, infective endocarditis | Recruiting | Phase 4 | 2026-07-07 | NCT05398679 | |
| Medical Device for Sustained Remission in Rheumatoid Arthritis Treated With Biological Therapy | Skin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, immune system disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis | Recruiting | Not applicable | 2026-07-01 | NCT07678112 | |
| A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), brain disorder, central nervous system cancer, central nervous system disorder, epithelial neoplasm, glioblastoma, glioma, neoplasm, nervous system disorder, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 3 | 2026-07-01 | NCT06388733 | |
| Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm | Recruiting | Not stated | 2026-06-03 | NCT07624838 | |
| Virtual Reality - Gamma Sensory Stimulation for Improving Fatigue in People With Multiple Sclerosis | CNS demyelinating autoimmune disease, Fatigue, Mental Fatigue, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Not yet recruiting | Not applicable | 2026-02-03 | NCT07310862 | |
| Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2025-09-09 | NCT04759248 | |
| HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a) | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, metastatic malignant neoplasm, neoplasm | Active, not recruiting | Not applicable | 2025-09-09 | NCT04257162 | |
| The Sagittarius Trial | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm | Recruiting | Phase 3 | 2025-08-29 | NCT06490536 | |
| Use of Intraoperative Radiotherapy in Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Enrolling by invitation | Not stated | 2025-07-31 | NCT07030231 | |
| Spanish Registry of Esophagogastric Cancer | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, esophageal cancer, esophageal disorder, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Not stated | 2025-07-03 | NCT04958720 | |
| Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Active, not recruiting | Phase 3 | 2025-06-17 | NCT05325593 | |
| RESTI Registry: Spanish Registry of Primary Immune Thrombocytopenia and Other Immune Thrombocytopenia | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Not stated | 2025-04-09 | NCT06919341 | |
| Rectal Tumor Resection Using the UNI-VEC Multichannel Transanal Access Device | polyp of rectum | Active, not recruiting | Not applicable | 2025-03-27 | NCT06286956 | |
| Autologous Tolerogenic Dendritic Cells (ATDC) for Highly Sensitized Kidney Transplant Recipients | Kidney Transplant Rejection | Not yet recruiting | Phase 1 | 2025-02-28 | NCT06852625 |